# OnCo record getug-13 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/getug-13/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "getug-13", "NCT00104676" ;
  schema:name "GETUG 13"@en ;
  schema:alternateName "GETUG-13"@en, "GETUG13"@en ;
  schema:description "GETUG 13 showed that men with the worst-risk testicular cancers whose tumour markers fall too slowly after the first cycle of chemotherapy do better if treatment is intensified: 59 percent were free of progression at three years against 48 percent with standard BEP, and fewer needed high-dose salvage chemotherapy."@en ;
  schema:url <https://onco.cc/trials/getug-13/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00104676> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/non-seminoma/>, <https://onco.cc/cancers/testicular/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/ifosfamide/> ;
  onco:institutions <https://onco.cc/institutions/unicancer/>, <https://onco.cc/institutions/md-anderson/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014/> .